Clinical Trial Update: A Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Stable Liver Transplantation Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing FK506MR with Prograf in stable liver transplant patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Transplantation

Drugs mentioned

• FK506MR (tacrolimus (modified-release))
• Prograf (Tacrolimus)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Liver Transplantation | Phase 3 | Status: COMPLETED